Inoue K, Okazaki K, Morimoto T, Hayashi M, Uyama S, Sonoo H, Koshiba Y, Takihara T, Nomura Y, Yamagata J, Kondo H, Kanda K, Takenaka K
Cancer Treat Rep. 1978 May;62(5):743-5.
A new, orally active antiestrogenic steroid, mepitiostane (20 mg/day), was given to 45 patients with advanced breast cancer. The regression rate was 31.1%, or 14 of 45 patients, and a duration of regression of greater than 6 months was obtained in seven patients. Virilizing effects such as hoarseness, hirsutism, and acne were observed relatively often, but there was no evidence of abnormality in the liver function tests or in the serum calcium level.
一种新型口服活性抗雌激素类固醇药物美替奥斯坦（每天20毫克）被给予45例晚期乳腺癌患者。缓解率为31.1%，即45例患者中有14例出现缓解，7例患者获得了超过6个月的缓解期。相对常见地观察到诸如声音嘶哑、多毛症和痤疮等男性化效应，但肝功能检查或血清钙水平均无异常迹象。
